From biomarker development towards implementation of multidimensional biomarker panels in a clinical setting

Molecular Oncology

Volumn 8, Issue 4, 2014, Pages 781-782

  van Kempen, Léon C ^a,b   Spatz, Alan ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; IMATINIB; MESSENGER RNA; MICRORNA; TRANSCRIPTOME; TUMOR MARKER;

ACCURACY; CHRONIC INFLAMMATION; DNA DAMAGE; EDITORIAL; GENE EXPRESSION; GENE MUTATION; IMMUNOHISTOCHEMISTRY; LIMIT OF DETECTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEOMICS; QUALITY CONTROL; TREATMENT RESPONSE; TUMOR GROWTH; CLASSIFICATION; DIAGNOSTIC PROCEDURE; GENETIC ASSOCIATION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; LYMPHOMA; MOLECULAR DIAGNOSIS; PROFESSIONAL PRACTICE; SARCOMA; TRENDS; VALIDATION STUDY;

DIAGNOSTIC TECHNIQUES AND PROCEDURES; GENETIC ASSOCIATION STUDIES; HUMANS; LYMPHOMA; MOLECULAR DIAGNOSTIC TECHNIQUES; PROFESSIONAL PRACTICE; PROGNOSIS; SARCOMA; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 84919332036     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.05.002     Document Type: Editorial

References (5)

1. Ascierto P.A., Kalos M., Schaer D.A., Callahan M.K., Wolchok J.D. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin. Cancer Res. 2013, 19:1009-10020.
2. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
3. Cavnar M.J., Zeng S., Kim T.S., Sorenson E.C., Ocuin L.M., Balachandran V.P., Seifert A.M., Greer J.B., Popow R., Crawley M.H., Cohen N.A., Green B.L., Rossi F., Besmer P., Antonescu C.R., DeMatteo R.P. KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J.Exp. Med. 2013, 210:2873-2886.
4. Erdem-Eraslan L., Gravendeel L.A., de Rooi J., Eilers P.H., Idbaih A., Spliet W.G., den Dunnen W.F., Teepen J.L., Wesseling P., Sillevis Smitt P.A., Kros J.M., Gorlia T., vanden Bent M.J., French P.J. Intrinsic molecular subtypes of glioma are prognostic and predict benefit fromadjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a reportfrom EORTC study 26951. J.Clin. Oncol. 2013, 31:328-336.
5. Kaplan R., Maughan T., Crook A., Fisher D., Wilson R., Brown L., Parmar M. Evaluating many treatments and biomarkers in oncology: a new design. J.Clin. Oncol. 2013, 31:4562-4568.